NEW DELHI, India — On January 30, 2026, the Central Drugs Standard Control Organization (CDSCO) reached a significant milestone in India’s medical device regulatory landscape by releasing a comprehensive draft guidance document for the import of In-vitro Diagnostic (IVD) medical devices. Aimed at bringing clarity to the industry, the document serves as a “how-to” manual for manufacturers and importers navigating the complex submission process through India’s digital portals.
For global manufacturers eyeing the Indian market, this draft is more than just a procedural update for medical device guidance ; it is a strategic roadmap intended to ensure completeness and accuracy in applications, thereby facilitating timely regulatory approvals.
MEDICAL DEVICE GUIDANCE IMPORTS NAVIGATING THE DUAL-PORTAL SYSTEM
The 2026 guidance reinforces the mandatory use of specific online platforms based on the intent of the import. Navigating these correctly is the first step toward compliance:
- Commercial Imports (Form MD-14): All applications for the grant of a registration, permission, or license for commercial sale and distribution must be submitted through the MD Online Portal (www.cdscomdonline.gov.in).
- Test & Evaluation (Form MD-16): Applications for “Test Licenses” used for clinical investigations, testing, evaluation, demonstration, or training must now be routed through the National Single Window System (NSWS) portal (https://www.nsws.gov.in/).
IN-VITRO DIAGNOSTIC (IVD) MEDICAL DEVICES A RISK-BASED APPROACH TO MARKET ACCESS
The CDSCO continues to align with global standards by categorizing all IVDs, including reagents, instruments, and software, into a four-tier risk classification system, as part of its medical device guidance.
This classification is essential for the CDSCO medical devices registration process:
Class A (Low Risk) | Basic reagents or lab equipment |
Class B (Low-Moderate Risk) | General diagnostic tests |
Class C (Moderate-High Risk) | Specialized diagnostic kits |
Class D (High Risk) | Critical tests for life-threatening conditions or high-impact diseases |
Key takeaway: The Central Licensing Authority (CLA) is the competent authority for issuing import licenses for all classes of IVD medical devices, as per medical device guidance 2026 and CDSCO guidelines for medical devices.
THE TECHNICAL DOSSIER: MASTERING THE CHECKLIST
The guidance provides an exhaustive breakdown of the documentation required for a successful submission. Manufacturers must pay close attention to the Device Master File (DMF) and Site Master File (SMF) requirements to avoid rejection.
CRITICAL COMPONENTS OF THE DMF INCLUDE:
- Analytical Studies: Detailed validation reports for three batches, including analytical sensitivity and specificity.
- Stability Studies: Comprehensive reports for at least three lots, covering shelf-life, in-use stability, and shipping stability.
- Performance Evaluation Reports (PER): Mandatory for specific high-risk devices, such as those for HIV, HBV, HCV, Cancer, Tuberculosis, and Malaria. These reports must be issued by a registered medical device testing laboratory in India.
- Post-Market Surveillance (PMS): Data and procedures collected by the manufacturer regarding complaints and corrective actions.
AVOIDING THE "SIGNATURE TRAP" AND OTHER PITFALLS
A highlight of the 2026 guidance is the “List of Common Non-Compliance Observed,” which provides a rare look at why applications fail. Major pitfalls include:
1. Signatory Discrepancies: Applications are frequently flagged when the legal form is signed by one person while the covering letter is signed by another.
2. Labeling Gaps: For test licenses, labels must explicitly state “For Evaluation Purpose Only, Not for Commercial Use”.
3. Authentication Issues: The Power of Attorney (POA) must be apostilled or authenticated by the Indian Embassy in the country of origin to be considered valid.
4. Language Barriers: Any documentation submitted in a foreign language must be accompanied by a notarized translation.
RESOURCES
To assist companies in navigating the new CDSCO guidelines for medical devices, the following references are highlighted within the CDSCO document:
- Classification Guidance: Detailed parameters for Class A (Low Risk) through Class D (High Risk) IVDs.
- Portal Links: Access the MD Online Portal for MD-14 applications and the NSWS Portal (National Single Window System) for MD-16 applications.
- Stability & Performance: Specific guidance on stability studies for IVDs and performance evaluation requirements for high-risk devices like HIV, HCV, and Cancer markers.
- Non-Compliance Checklist: A list of common errors, such as mismatched addresses in the Power of Attorney (POA) or missing digital signatures, to help manufacturers avoid “Query Raised” delays.